Deepeye Medical
Precision health platform to improve therapy against blindness using AI.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
N/A | Seed | ||
| Total Funding | 000k | ||
| EUR | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 33 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
DeepEye Medical is a pioneering startup in the healthcare sector, specifically in the field of ophthalmology. The company is leveraging artificial intelligence (AI) to revolutionize retinal therapy, a critical area of eye care that can prevent up to 66% of blindness cases in Europe and the US. DeepEye's primary offering is a digital therapy assistant, an AI tool that aids doctors in making more informed decisions, thereby improving patient outcomes.
DeepEye's AI tool is based on a clinically proven method that has shown to yield three times better outcomes and retain twice as many patients in vision-preserving treatment compared to conventional methods. The tool is designed to reduce the therapy burden on clinicians and patients, improving treatment adherence, and boosting therapy effectiveness and efficiency. This is particularly important given the growing prevalence of retinal diseases worldwide.
The company has made its AI tool easy to adopt by ensuring seamless integration with popular imaging software and collaboration with major OCT device manufacturers. This lowers the barrier to entry and simplifies the transition to DeepEye's platform. The company is the first to launch a retinal treatment support tool with device-agnostic AI, now embedded in major OCT manufacturers' software for enhanced 3D eye scan data analysis.
DeepEye is also revolutionizing clinical studies with its research platform, deepeye® Research. This AI platform is transforming retinal therapy research, offering unparalleled insights and efficiency to study teams across pharmaceuticals, medical devices, and payors.
In terms of business model, DeepEye likely generates revenue by selling its AI tools to healthcare providers and through partnerships with pharmaceutical and medical device companies for its research platform.
Keywords: Healthcare, Ophthalmology, Retinal Therapy, Artificial Intelligence, Digital Therapy Assistant, Clinical Studies, Eye Care, Medical Devices, Pharmaceuticals, Research Platform.